查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1882976

美容神經毒素市場規模、佔有率、成長及全球產業分析：按類型、應用和地區劃分的洞察與預測（2024-2032 年）

Aesthetic Neurotoxin Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 159 Pages | 商品交期: 請詢問到貨日

價格

美容神經毒素市場成長驅動因素

由於對微創美容手術的需求不斷增長以及消費者對美容效果的接受度日益提高，全球美容神經毒素市場持續擴張。根據本報告，預計該市場在 2024 年的規模將達到 52.5 億美元，並在 2025 年達到 56 億美元。預計到 2032 年，該市場將進一步成長至 91.2 億美元，預測期內複合年增長率 (CAGR) 為 7.2%。北美地區在全球市場中佔領先地位，預計到 2024 年將佔 51.62% 的市場佔有率，這主要得益於其先進的醫療基礎設施、較高的患者支出以及對美容手術的廣泛接受。

美容神經毒素（通常稱為肉毒桿菌注射）是一種非手術療法，旨在實現臉部年輕化和減少皺紋。美容手術在各個年齡層的日益普及以及社會對美容手術接受度的不斷提高，是推動市場成長的關鍵因素。此外，醫療美容旅遊也顯著促進了該行業的發展，例如韓國等國家國際患者就診量激增。預計2023年將有605,768名醫療旅客到訪韓國，比2022年增加144.2%。

市場動態

市場驅動因素

對微創美容療法的需求正在蓬勃發展，尤其是在尋求早期抗衰老幹預的年輕一代。根據美國美容外科學會2022年的報告，美容手術總量增加了14%，而非手術療法則實現了顯著的23%的增長。肉毒桿菌注射是最受歡迎的美容方式，預計2022年將進行887萬例。已開發國家和新興國家可支配收入的成長進一步推動了美容神經毒素的普及。

市場限制因子

儘管需求強勁，但美容神經毒素的副作用（例如腫脹、瘀傷、眼瞼下垂、頭痛和暫時性肌肉無力）限制了其市場發展。高昂的治療費用也構成了一大障礙。據Direct Aesthetics PLLC稱，在美國，肉毒桿菌治療的平均費用為每次450美元，價格範圍從200美元到1200美元不等。這樣的價格限制了低收入患者接受治療，並增加了假冒產品的風險。

市場機會

對更安全、更持久、免疫原性更低的神經毒素製劑的需求不斷增長，推動了研發投入的增加。各公司正在開發新型重組肉毒桿菌毒素，旨在最大限度地減少副作用並延長美容效果。 2023年10月，艾伯維公司宣布了其用於治療眉間紋的重組肉毒桿菌毒素E (BoNT/E) III期臨床試驗的積極結果，凸顯了其產品線持續創新。

市場挑戰

假神經毒素產品的氾濫對病人安全構成重大風險，並可能損害消費者對正品的信任。 2024年6月，美國疾病管制與預防中心 (CDC) 報告稱，美國九個州的17人在接受假神經毒素注射後出現不良反應。此類事件對收入成長構成挑戰，並凸顯了嚴格監管的必要性。

市場趨勢

技術進步，包括重組肉毒桿菌毒素的研發，是該產業的主要趨勢。重組製劑具有免疫原性較低、療效持續時間較長等優點，因此安全性較高。 2024年9月，明美生物技術有限公司的首個液態重組A型肉毒桿菌毒素製劑 "YY003" 獲得美國FDA的IND批准，用於治療眉間紋，這標誌著該行業正朝著下一代神經毒素的方向發展。

細分市場洞察

按應用領域

2024年，眉間紋細分市場佔主導地位，這主要得益於市場需求旺盛以及強有力的臨床證據支持其療效。額頭皺紋市場也佔了相當大的佔有率，這主要得益於美國FDA於2023年批准XEOMIN用於治療多種上臉部皺紋。魚尾紋市場也持續成長，因為這些細紋仍然是常見的美容問題。

依最終使用者劃分

專科診所和皮膚科診所在2024年佔了最大的收入佔有率。廣泛的美容服務和積極的醫療旅遊是推動患者選擇的主要因素。醫院和診所也保持了相當大的佔有率，2023年美國24.5%的美容手術是在醫院進行的。

區域洞察

北美地區繼續保持其主導地位，在2024年市場規模達到27.1億美元，這主要得益於較高的手術量和快速的監管審批。美國佔了區域需求的大部分，2023年進行了440萬例非手術美容療程。

歐洲維持了較大的市場佔有率，這得益於人口老化和皮膚再生療法的廣泛應用。

由於美容療程的普及以及重要的區域合作，例如華東醫學美容與ATGC株式會社的合作，亞太地區預計將以最高的複合年增長率增長。

由於可支配收入的增加以及諸如大元製藥在卡達推出的 "NABOTA" （2025年上市）等產品的上市，拉丁美洲和中東/非洲的需求也在增長。

目錄

第一章：引言

第二章：摘要整理

第三章：市場動態

  • 市場驅動因素
  • 市場限制因素
  • 市場機遇
  • 市場趨勢

第四章：主要發現

  • 主要國家美容手術量概覽
  • 以美容手術類型劃分的價格分析概覽
  • 主要國家監理狀況概覽
  • 主要國家報銷狀況概覽
  • 主要公司新產品發布
  • 主要公司在研產品線分析
  • 經厚生勞動省核准的主要美容神經毒素產品進口和銷售概覽福利（日本）

第五章：全球美容神經毒素市場分析、洞察與預測（2019-2032）

  • 市場分析、洞察與預測 - 按應用領域劃分
    • 額紋
    • 眉間紋
    • 魚尾紋
    • 其他
  • 市場分析、洞察與預測 - 按最終用戶劃分
    • 專科診所及皮膚科診所
    • 醫院和診所
    • 其他
  • 市場分析、洞察與預測 - 按地區劃分
    • 北美
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第六章 北美美容市場神經毒素市場分析、洞察與預測（2019-2032）

  • 依國家劃分
    • 美國
    • 加拿大

第七章：歐洲化妝品神經毒素市場分析、洞察與預測（2019-2032）

  • 依國家劃分
    • 英國
    • 德國
    • 法國
    • 西班牙
    • 義大利
    • 斯堪的納維亞
    • 烏克蘭
    • 歐洲其他地區

第八章：亞太地區化妝品神經毒素市場分析、洞察與預測（2019-2032）

  • 依國家/地區
    • 日本
    • 中國
    • 印度
    • 澳大利亞
    • 韓國
    • 泰國
    • 台灣
    • 亞太其他地區

第九章：拉丁美洲化妝品神經毒素市場分析、洞察與預測（2019-2032）

  • 依國家劃分
    • 巴西
    • 墨西哥
    • 智利
    • 哥倫比亞
    • 拉丁美洲其他地區

第十章：中東和非洲化妝品神經毒素市場分析、洞察與預測（2019-2032）

  • 依國家/地區
    • 埃及
    • 伊朗
    • 土耳其
    • 黎巴嫩
    • 阿拉伯聯合大公國
    • 沙烏地阿拉伯
    • 南非
    • 中東和非洲其他地區

第十一章 競爭分析

  • 全球市佔率分析（2024 年）
  • 公司簡介
    • 艾伯維公司（Allergen Aesthetics）
    • 益普生製藥
    • 默茲製藥
    • HUGEL 公司
    • Evolus 公司
    • 高德美
    • REVANCE
    • Supernus Pharmaceuticals 公司
    • Medytox
    • 上海復星醫藥（集團）有限公司
    • 大王製藥藥廠
Product Code: FBI113750

Growth Factors of aesthetic neurotoxin Market

The global aesthetic neurotoxin market continues to expand due to rising demand for minimally invasive cosmetic procedures and increasing consumer acceptance of aesthetic enhancements. According to the report, the market was valued at USD 5.25 billion in 2024, is expected to reach USD 5.60 billion in 2025, and is projected to grow significantly to USD 9.12 billion by 2032, reflecting a CAGR of 7.2% during the forecast period. North America led the global market in 2024 with a 51.62% share, driven by advanced healthcare infrastructure, high patient spending, and strong adoption of aesthetic procedures.

Aesthetic neurotoxins, widely recognized as botulinum toxin injections, offer a non-surgical alternative for facial rejuvenation and wrinkle reduction. The increasing normalization of aesthetic procedures across generations and growing social acceptance of cosmetic enhancements are major contributors to market growth. Additionally, cosmetic tourism significantly boosts the industry, with countries like South Korea witnessing sharp increases in foreign patient visits-605,768 medical tourists in 2023, representing a 144.2% rise from 2022.

Market Dynamics

Market Drivers

Demand for minimally invasive aesthetic treatments continues to surge, particularly among younger consumers seeking early anti-aging interventions. The Aesthetic Society's 2022 report documented a 14% rise in total aesthetic procedures and a remarkable 23% growth in non-surgical treatments. Botulinum toxin injections remained the most popular, accounting for 8.87 million procedures in 2022. Rising disposable incomes in both developed and emerging economies further fuel the uptake of aesthetic neurotoxins.

Market Restraints

Despite strong demand, adverse effects associated with aesthetic neurotoxins-such as swelling, bruising, droopy eyelids, headaches, and temporary muscle weakness-pose restraints. High treatment costs also reduce accessibility. According to Direct Aesthetics PLLC, Botox treatments in the U.S. cost an average of USD 450, ranging from USD 200 to USD 1,200 per session. Such pricing limits access for lower-income patients and increases the risk of counterfeit product use.

Market Opportunities

R&D initiatives are expanding due to rising demand for safer, long-lasting, and less immunogenic neurotoxin formulations. Companies are developing new recombinant botulinum toxins designed to minimize adverse effects and extend cosmetic benefits. In October 2023, AbbVie announced positive Phase 3 results for trenibotulinumtoxinE (BoNT/E) for glabellar lines, highlighting ongoing innovation in product pipelines.

Market Challenges

The proliferation of counterfeit neurotoxin products poses a major risk to patient safety and diminishes trust in legitimate brands. The CDC reported in June 2024 that 17 individuals across nine U.S. states experienced harmful reactions after receiving counterfeit neurotoxin injections. Such incidents challenge revenue growth and reinforce the need for strict regulatory oversight.

Market Trends

Technological advancements-including the development of recombinant botulinum toxin-represent a major industry trend. Recombinant formulations are less immunogenic and offer safer alternatives with improved duration of effect. In September 2024, MingMed Biotechnology secured U.S. FDA IND approval for YY003, the first liquid recombinant BoNT/A for glabellar lines, demonstrating industry momentum toward next-generation neurotoxins.

Segmentation Insights

By Application

The glabellar lines segment dominated the market in 2024 due to high demand and robust clinical evidence supporting treatment effectiveness. Forehead wrinkles also recorded significant share, driven by the 2023 U.S. FDA approval of XEOMIN for multiple upper facial lines. The crow's feet segment continues to expand as these fine lines remain a common aesthetic concern.

By End-User

Specialty & dermatology clinics accounted for the largest revenue share in 2024. Their wide range of cosmetic services and strong participation in medical tourism drive patient preference. Hospitals & clinics also maintained a considerable share, with 24.5% of U.S. cosmetic procedures in 2023 performed in hospital settings.

Regional Insights

North America generated USD 2.71 billion in 2024, maintaining dominance due to high procedure volume and rapid regulatory approvals. The U.S. accounted for the majority of regional demand, with 4.4 million non-surgical aesthetic procedures in 2023.

Europe held substantial share fueled by aging demographics and strong adoption of skin rejuvenation treatments.

Asia Pacific is projected to grow at the fastest CAGR, supported by normalization of cosmetic procedures and major regional collaborations-such as the partnership between Huadong Medicine Aesthetics and ATGC Co. Ltd.

Latin America and Middle East & Africa show rising demand due to growing disposable income and product launches like Daewoong's NABOTA in Qatar (2025).

Conclusion

With market revenue rising from USD 5.25 billion in 2024 to USD 9.12 billion by 2032, the aesthetic neurotoxin industry is poised for strong growth. Increased acceptance of cosmetic enhancements, technological advancements, expanding medical tourism, and strategic industry partnerships will continue to shape the global landscape.

Segmentation By Application

  • Forehead Wrinkles
  • Glabellar Lines
  • Crow's Feet
  • Others

By End-User

  • Specialty & Dermatology Clinics
  • Hospitals & Clinics
  • Others

By Region

  • North America (By Application, End-User, and Country)
    • U.S. (By Application)
    • Canada (By Application)
  • Europe (By Application, End-User, and Country)
    • Germany (By Application)
    • U.K. (By Application)
    • France (By Application)
    • Italy (By Application)
    • Spain (By Application)
    • Scandinavia (By Application)
    • Ukraine (By Application)
    • Rest of Europe (By Application)
  • Asia Pacific (By Application, End-User, and Country /sub-region)
    • China (By Application)
    • India (By Application)
    • Japan (By Application)
    • Australia (By Application)
    • South Korea (By Application)
    • Thailand (By Application)
    • Taiwan (By Application)
    • Rest of the Asia Pacific (By Application)
  • Latin America (By Application, End-User, and Country /sub-region)
    • Brazil (By Application)
    • Mexico (By Application)
    • Colombia (By Application)
    • Argentina (By Application)
    • Venezuela (By Application)
    • Chile (By Application)
    • Rest of Latin America (By Application)
  • Middle East & Africa (By Application, End-User, and Country /sub-region)
    • UAE (By Application)
    • Saudi Arabia (By Application)
    • Rest of GCC (By Application)
    • South Africa (By Application)
    • Turkey (By Application)
    • Egypt (By Application)
    • Lebanon (By Application)
    • Iran (By Application)
    • Rest of the Middle East & Africa (By Application)

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Overview of the Number of Aesthetic Procedures, By Key Countries
  • 4.2. Overview of Price Analysis of Types of Aesthetic Procedures
  • 4.3. Overview of Regulatory Scenario, By Key Countries
  • 4.4. Overview of Reimbursement Scenario, By Key Countries
  • 4.5. New Product Launches, By Key Players
  • 4.6. Pipeline Analysis, By Key Players
  • 4.7. Imports/Sales Overview of Key Aesthetic Neurotoxin Products Approved by MHLW (Japan)

5. Global Aesthetic Neurotoxin Market Analysis, Insights and Forecast, 2019-2032

  • 5.1. Market Analysis, Insights and Forecast - By Application
    • 5.1.1. Forehead Wrinkles
    • 5.1.2. Glabellar Lines
    • 5.1.3. Crow's Feet
    • 5.1.4. Others
  • 5.2. Market Analysis, Insights and Forecast - By End-User
    • 5.2.1. Specialty & Dermatology Clinics
    • 5.2.2. Hospitals & Clinics
    • 5.2.3. Others
  • 5.3. Market Analysis, Insights and Forecast - Region
    • 5.3.1. North America
    • 5.3.2. Europe
    • 5.3.3. Asia Pacific
    • 5.3.4. Latin America
    • 5.3.5. Middle East & Africa

6. North America Aesthetic Neurotoxin Market Analysis, Insights and Forecast, 2019-2032

  • 6.1. Market Analysis, Insights and Forecast - By Application
    • 6.1.1. Forehead Wrinkles
    • 6.1.2. Glabellar Lines
    • 6.1.3. Crow's Feet
    • 6.1.4. Others
  • 6.2. Market Analysis, Insights and Forecast - By End-User
    • 6.2.1. Specialty & Dermatology Clinics
    • 6.2.2. Hospitals & Clinics
    • 6.2.3. Others
  • 6.3. Market Analysis, Insights and Forecast - By Country
    • 6.3.1. U.S.
    • 6.3.2. Canada

7. Europe Aesthetic Neurotoxin Market Analysis, Insights and Forecast, 2019-2032

  • 7.1. Market Analysis, Insights and Forecast - By Application
    • 7.1.1. Forehead Wrinkles
    • 7.1.2. Glabellar Lines
    • 7.1.3. Crow's Feet
    • 7.1.4. Others
  • 7.2. Market Analysis, Insights and Forecast - By End-User
    • 7.2.1. Specialty & Dermatology Clinics
    • 7.2.2. Hospitals & Clinics
    • 7.2.3. Others
  • 7.3. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 7.3.1. U.K.
    • 7.3.2. Germany
    • 7.3.3. France
    • 7.3.4. Spain
    • 7.3.5. Italy
    • 7.3.6. Scandinavia
    • 7.3.7. Ukraine
    • 7.3.8. Rest of Europe

8. Asia Pacific Aesthetic Neurotoxin Market Analysis, Insights and Forecast, 2019-2032

  • 8.1. Market Analysis, Insights and Forecast - By Application
    • 8.1.1. Forehead Wrinkles
    • 8.1.2. Glabellar Lines
    • 8.1.3. Crow's Feet
    • 8.1.4. Others
  • 8.2. Market Analysis, Insights and Forecast - By End-User
    • 8.2.1. Specialty & Dermatology Clinics
    • 8.2.2. Hospitals & Clinics
    • 8.2.3. Others
  • 8.3. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 8.3.1. Japan
    • 8.3.2. China
    • 8.3.3. India
    • 8.3.4. Australia
    • 8.3.5. South Korea
    • 8.3.6. Thailand
    • 8.3.7. Taiwan
    • 8.3.8. Rest of Asia Pacific

9. Latin America Aesthetic Neurotoxin Market Analysis, Insights and Forecast, 2019-2032

  • 9.1. Market Analysis, Insights and Forecast - By Application
    • 9.1.1. Forehead Wrinkles
    • 9.1.2. Glabellar Lines
    • 9.1.3. Crow's Feet
    • 9.1.4. Others
  • 9.2. Market Analysis, Insights and Forecast - By End-User
    • 9.2.1. Specialty & Dermatology Clinics
    • 9.2.2. Hospitals & Clinics
    • 9.2.3. Others
  • 9.3. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 9.3.1. Brazil
    • 9.3.2. Mexico
    • 9.3.3. Chile
    • 9.3.4. Colombia
    • 9.3.5. Rest of Latin America

10. Middle East & Africa Aesthetic Neurotoxin Market Analysis, Insights and Forecast, 2019-2032

  • 10.1. Market Analysis, Insights and Forecast - By Application
    • 10.1.1. Forehead Wrinkles
    • 10.1.2. Glabellar Lines
    • 10.1.3. Crow's Feet
    • 10.1.4. Others
  • 10.2. Market Analysis, Insights and Forecast - By End-User
    • 10.2.1. Specialty & Dermatology Clinics
    • 10.2.2. Hospitals & Clinics
    • 10.2.3. Others
  • 10.3. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 10.3.1. Egypt
    • 10.3.2. Iran
    • 10.3.3. Turkey
    • 10.3.4. Lebanon
    • 10.3.5. UAE
    • 10.3.6. Saudi Arabia
    • 10.3.7. South Africa
    • 10.3.8. Rest of Middle East and Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2024)
  • 11.2. Company Profiles
    • 11.2.1. AbbVie Inc. (Allergen Aesthetics)
      • 11.2.1.1. Overview
      • 11.2.1.2. Products
      • 11.2.1.3. SWOT Analysis
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. Financials (Based on Availability)
    • 11.2.2. Ipsen Pharma
      • 11.2.2.1. Overview
      • 11.2.2.2. Products
      • 11.2.2.3. SWOT Analysis
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. Financials (Based on Availability)
    • 11.2.3. Merz Pharma
      • 11.2.3.1. Overview
      • 11.2.3.2. Products
      • 11.2.3.3. SWOT Analysis
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. Financials (Based on Availability)
    • 11.2.4. HUGEL, Inc.
      • 11.2.4.1. Overview
      • 11.2.4.2. Products
      • 11.2.4.3. SWOT Analysis
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. Financials (Based on Availability)
    • 11.2.5. Evolus, Inc.
      • 11.2.5.1. Overview
      • 11.2.5.2. Products
      • 11.2.5.3. SWOT Analysis
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. Financials (Based on Availability)
    • 11.2.6. GALDERMA
      • 11.2.6.1. Overview
      • 11.2.6.2. Products
      • 11.2.6.3. SWOT Analysis
      • 11.2.6.4. Recent Developments
      • 11.2.6.5. Strategies
      • 11.2.6.6. Financials (Based on Availability)
    • 11.2.7. REVANCE
      • 11.2.7.1. Overview
      • 11.2.7.2. Products
      • 11.2.7.3. SWOT Analysis
      • 11.2.7.4. Recent Developments
      • 11.2.7.5. Strategies
      • 11.2.7.6. Financials (Based on Availability)
    • 11.2.8. Supernus Pharmaceuticals, Inc.
      • 11.2.8.1. Overview
      • 11.2.8.2. Products
      • 11.2.8.3. SWOT Analysis
      • 11.2.8.4. Recent Developments
      • 11.2.8.5. Strategies
      • 11.2.8.6. Financials (Based on Availability)
    • 11.2.9. Medytox
      • 11.2.9.1. Overview
      • 11.2.9.2. Products
      • 11.2.9.3. SWOT Analysis
      • 11.2.9.4. Recent Developments
      • 11.2.9.5. Strategies
      • 11.2.9.6. Financials (Based on Availability)
    • 11.2.10. Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
      • 11.2.10.1. Overview
      • 11.2.10.2. Products
      • 11.2.10.3. SWOT Analysis
      • 11.2.10.4. Recent Developments
      • 11.2.10.5. Strategies
      • 11.2.10.6. Financials (Based on Availability)
    • 11.2.11. DAEWOONG PHARMACEUTICAL CO., LTD
      • 11.2.11.1. Overview
      • 11.2.11.2. Products
      • 11.2.11.3. SWOT Analysis
      • 11.2.11.4. Recent Developments
      • 11.2.11.5. Strategies
      • 11.2.11.6. Financials (Based on Availability)

List of Tables

  • Table 1: Global Aesthetic Neurotoxin Market Revenue (USD billion) Forecast, by Application, 2019-2032
  • Table 2: Global Aesthetic Neurotoxin Market Revenue (USD billion) Forecast, by End-User, 2019-2032
  • Table 3: Global Aesthetic Neurotoxin Market Revenue (USD billion) Forecast, by Region, 2019-2032
  • Table 4: North America Aesthetic Neurotoxin Market Revenue (USD billion) Forecast, by Application, 2019-2032
  • Table 5: North America Aesthetic Neurotoxin Market Revenue (USD billion) Forecast, by End-User, 2019-2032
  • Table 6: North America Aesthetic Neurotoxin Market Revenue (USD billion) Forecast, by Country, 2019-2032
  • Table 7: Europe Aesthetic Neurotoxin Market Revenue (USD billion) Forecast, by Application, 2019-2032
  • Table 8: Europe Aesthetic Neurotoxin Market Revenue (USD billion) Forecast, by End-User, 2019-2032
  • Table 9: Europe Aesthetic Neurotoxin Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2019-2032
  • Table 10: Asia Pacific Aesthetic Neurotoxin Market Revenue (USD billion) Forecast, by Application, 2019-2032
  • Table 11: Asia Pacific Aesthetic Neurotoxin Market Revenue (USD billion) Forecast, by End-User, 2019-2032
  • Table 12: Asia Pacific Aesthetic Neurotoxin Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2019-2032
  • Table 13: Latin America Aesthetic Neurotoxin Market Revenue (USD billion) Forecast, by Application, 2019-2032
  • Table 14: Latin America Aesthetic Neurotoxin Market Revenue (USD billion) Forecast, by End-User, 2019-2032
  • Table 15: Latin America Aesthetic Neurotoxin Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2019-2032
  • Table 16: Middle East & Africa Aesthetic Neurotoxin Market Revenue (USD billion) Forecast, by Application, 2019-2032
  • Table 17: Middle East & Africa Aesthetic Neurotoxin Market Revenue (USD billion) Forecast, by End-User, 2019-2032
  • Table 18: Middle East & Africa Aesthetic Neurotoxin Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2019-2032

List of Figures

  • Table 1: Global Aesthetic Neurotoxin Market Revenue (USD billion) Forecast, by Application, 2019-2032
  • Table 2: Global Aesthetic Neurotoxin Market Revenue (USD billion) Forecast, by End-User, 2019-2032
  • Table 3: Global Aesthetic Neurotoxin Market Revenue (USD billion) Forecast, by Region, 2019-2032
  • Table 4: North America Aesthetic Neurotoxin Market Revenue (USD billion) Forecast, by Application, 2019-2032
  • Table 5: North America Aesthetic Neurotoxin Market Revenue (USD billion) Forecast, by End-User, 2019-2032
  • Table 6: North America Aesthetic Neurotoxin Market Revenue (USD billion) Forecast, by Country, 2019-2032
  • Table 7: Europe Aesthetic Neurotoxin Market Revenue (USD billion) Forecast, by Application, 2019-2032
  • Table 8: Europe Aesthetic Neurotoxin Market Revenue (USD billion) Forecast, by End-User, 2019-2032
  • Table 9: Europe Aesthetic Neurotoxin Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2019-2032
  • Table 10: Asia Pacific Aesthetic Neurotoxin Market Revenue (USD billion) Forecast, by Application, 2019-2032
  • Table 11: Asia Pacific Aesthetic Neurotoxin Market Revenue (USD billion) Forecast, by End-User, 2019-2032
  • Table 12: Asia Pacific Aesthetic Neurotoxin Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2019-2032
  • Table 13: Latin America Aesthetic Neurotoxin Market Revenue (USD billion) Forecast, by Application, 2019-2032
  • Table 14: Latin America Aesthetic Neurotoxin Market Revenue (USD billion) Forecast, by End-User, 2019-2032
  • Table 15: Latin America Aesthetic Neurotoxin Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2019-2032
  • Table 16: Middle East & Africa Aesthetic Neurotoxin Market Revenue (USD billion) Forecast, by Application, 2019-2032
  • Table 17: Middle East & Africa Aesthetic Neurotoxin Market Revenue (USD billion) Forecast, by End-User, 2019-2032
  • Table 18: Middle East & Africa Aesthetic Neurotoxin Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2019-2032